View text source at Wikipedia

ADB-4en-PINACA

ADB-4en-PINACA
Legal status
Legal status
Identifiers
  • N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H26N4O2
Molar mass342.443 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)c1nn(CCCC=C)c2ccccc21)C(C)(C)C
  • InChI=1S/C19H26N4O2/c1-5-6-9-12-23-14-11-8-7-10-13(14)15(22-23)18(25)21-16(17(20)24)19(2,3)4/h5,7-8,10-11,16H,1,6,9,12H2,2-4H3,(H2,20,24)(H,21,25)
  • Key:NXDLAZXBALPFSN-UHFFFAOYSA-N

ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products,[1] first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.[2][3][4][5]

Legality

[edit]

In the United States, the DEA has temporarily placed ADB-4en-PINACA into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12th, 2025.[6]

See also

[edit]

References

[edit]
  1. ^ Nuclear magnetic resonance implemented synthetic indole and indazole cannabinoid detection, identification, and quantification
  2. ^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (April 2022). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
  3. ^ Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors". Drug Testing and Analysis. 13 (7): 1383–1401. doi:10.1002/dta.3037. PMID 33787091.
  4. ^ Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays-Part II: Structure activity relationship assessment via a β-arrestin recruitment assay". Drug Testing and Analysis. 13 (7): 1402–1411. doi:10.1002/dta.3035. PMID 33769699.
  5. ^ Grafinger KE, Vandeputte MM, Cannaert A, Ametovski A, Sparkes E, Cairns E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays". Drug Testing and Analysis. 13 (7): 1412–1429. doi:10.1002/dta.3054. hdl:1854/LU-8720689. PMID 33908179.
  6. ^ "Federal Register :: Request Access".